Created at	Source	Raw Value	Validated value
Sept. 27, 2021, 7:30 a.m.	usa	The number of participants with AEs following administration of ADM03820 to the final visit;The number of participants with changes from baseline in physical examination, vital signs and clinical safety laboratory values following administration of ADM03820 to the final visit;The number of participants with Serious Adverse Events following administration of ADM03820 to the final visit	The number of participants with AEs following administration of ADM03820 to the final visit;The number of participants with changes from baseline in physical examination, vital signs and clinical safety laboratory values following administration of ADM03820 to the final visit;The number of participants with Serious Adverse Events following administration of ADM03820 to the final visit
Oct. 26, 2020, 11:31 p.m.	usa	The number of participants with Serious Adverse Events following administration of ADM03820 to the final visit;The number of participants with AEs from administration of ADM03820 to the final visit	The number of participants with Serious Adverse Events following administration of ADM03820 to the final visit;The number of participants with AEs from administration of ADM03820 to the final visit